Journal of Hepatology
Volume 54, Issue 1 , Pages 72-77, January 2011

Sub-clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam: A randomized controlled study

  • Iyad Khamaysi

      Affiliations

    • Department of Gastroenterology, Rambam Medical Center, Haifa, Israel
  • ,
  • Nseir William

      Affiliations

    • Internal Medicine, Holy Family Hospital, Nazareth, Israel
  • ,
  • Alexandrov Olga

      Affiliations

    • Department of Anesthesia, Ziv Medical Centre, Safed, Israel
  • ,
  • Isakson Alex

      Affiliations

    • Department of Anesthesia, Ziv Medical Centre, Safed, Israel
  • ,
  • Mysh Vladimir

      Affiliations

    • Department of Gastroenterology, Ziv Medical Centre, Safed, Israel
  • ,
  • Dabbah Kamal

      Affiliations

    • Department of Gastroenterology, Ziv Medical Centre, Safed, Israel
  • ,
  • Assy Nimer

      Affiliations

    • Liver Unit, Ziv Medical Center, Safed, Israel
    • Technion Institute, Rappaport Faculty of Medicine, Haifa, Israel
    • Corresponding Author InformationCorresponding author at: Liver Unit, Ziv Medical Center, POB 1008, Safed 13100, Israel. Tel.: +972 4 682 8441/5; fax: +972 4 682 8442.

Received 3 March 2010; received in revised form 14 June 2010; accepted 14 June 2010. published online 31 August 2010.

Background & Aims

The risk of exacerbating sub-clinical hepatic encephalopathy (HE) by propofol has not been established. The aim of this study is to determine whether the use of propofol, for upper endoscopy in patients with cirrhosis, precipitates sub-clinical HE.

Methods

Sixty-one patients with compensated HCV and HBV cirrhosis (CP score 5–6) were randomly selected and divided into two groups (intent-to-treat population) matched for age, gender, and BMI. The first group received a single propofol sedation (N=31, age 57±12, dose range 70–100mg/procedure) and the second group (N=30, age 56±12, dose 3–6mg/procedure) received a single midazolam sedation, all done by an anesthesiologist. All patients completed number connection test (NCT), cognitive function score, time to recovery, time to discharge sheets, and hemodynamic parameters before sedation, and at discharge from the endoscopy unit, 1h post-procedure. Thirty control subjects without cirrhosis were matched to the cirrhotic patients who received sedation with regard to age, gender, BMI, and education level.

Results

A total of 58/61 cirrhotic patients (95%) had sub-clinical encephalopathy before the endoscopy (mean NCT 84.7±77s, normal <30s). No patient developed overt HE after sedation. There were no differences between groups in the incidence of adverse effects, cognitive function, MELD score, CP score, oxygen saturation, or respiratory and heart rates before and after sedation. Propofol did not exacerbate minimal HE when compared to midazolam (NCT changed from 87.5±62s prior to sedation to 74.2±58s after sedation in the propofol group versus 72.8±62s before to 85.6±72s after sedation in the midazolam group; p<0.01). Time to recovery (4.1±1.9min vs. 11.5±5.0min, p<0.001), and time to discharge (38.0±9min vs. 110±42min, p<0.001) were significantly shorter with propofol than midazolam. Pre- and post-procedure NCT (from 25±20s to 24±20s), cognitive function score (from 25 to 26), time to recovery (3.5±1.0min), and time to discharge (35±10min) did not change in the healthy controls.

Conclusions

Sedation with propofol has a shorter time recovery and a shorter time to discharge than midazolam and does not exacerbate sub-clinical hepatic encephalopathy in patients with compensated liver cirrhosis.

Abbreviations: HE, hepatic encephalopathy, CP, Child-Pugh’s score, NCT, number connection test, GI, gastro intestinal, GABA, γ-amino butyric acid, BMI, body mass index, ALT, alanine aminotransferases, AST, aspartate aminotransferases, GGT, gamma glutamyl tranferases, MELD, model of end stage liver disease, RR, respiratory rate, HR, heart rate, ANOVA, analysis of variance

Keywords: Sedation, Endoscopy, Midazolam, Propofol, Cirrhosis, Encephalopathy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0168-8278(10)00713-0

doi:10.1016/j.jhep.2010.06.023

Journal of Hepatology
Volume 54, Issue 1 , Pages 72-77, January 2011